USP に基づくペプチドの配合 795 & 797: 品質境界の説明

なぜ複利的な精査が研究調達を再構築しているのか

過去10年間のほとんどにおいて, 「配合」という用語はペプチドの文脈では狭い意味を持っていました: 薬局で調製された患者向けの注射用製剤, 主に 503A 患者固有の製剤と, より大きな規模で, 503B 施設運営のアウトソーシング. この活動の品質ガバナンス フレームワーク — USP <797> 無菌製剤用, 米国薬局 <795> 非滅菌の場合 — 主に薬局運営の問題でした.

GLP-1受容体アゴニストの需要に伴ってペプチド配合量が劇的に増加したとき、その枠組みは変化しました。, 遠隔医療によるペプチド処方, そしてコンシューマーウェルネス市場. の FDA 薬局調剤諮問委員会の会議資料 (7月 2026) FDAは配合ペプチド市場をこれまでよりも大幅に厳しい監視が必要であると考えていることを明らかにする. 強制措置, 原薬のバルク調達に関する輸入アラート, そして、503A/503B 合成経路からのいくつかのペプチド配列の正式な除外はすべてその後に行われました。.

研究調達における下流効果は有意義である. 調合業者が身元を文書化する方法を規制当局が精査するとき, 純度, 無菌性, およびその出発原料の出所, 彼らは、調合者だけでなく、「適切な」ペプチド文書がどのようなものであるかを定義する品質の下限を暗黙のうちに設定しています。, ただし、同じ監査コンテキストで材料がレビューされるサプライヤーの場合は対象となります。.

Rさんへの質問&D 意思決定者は「USP を行う」ではない <797> 私のカスタム合成オーダーに適用する?” 質問は: 「私のサプライヤーの文書は、配合品質の審査員が現在適用している精査レベルに耐えられるでしょうか？」?」

カテゴリの定義: 規制の境界線が実際にどこに当てはまるのか

精査が何を要求しているかを議論する前に, ペプチド供給の各カテゴリが実際に何であるかを確立することは価値があります。なぜなら、これらのカテゴリの混同は調達リスクの主な原因だからです。.

503配合

連邦食品法第 503A 条に基づく, 薬, および化粧品法, 認可された薬剤師または医師は、有効な処方箋を持って特定された患者のために原薬から医薬品を調合することができます。. 完成した製剤はFDAの承認を受けていません. あたり FDAの調合に関するよくある質問, 503A製剤は主に州の薬局委員会によって監督されており、市販前の承認は免除されている, cGMP, および特定のラベル表示要件 - すべての法定条件が満たされている場合に限ります. 注射可能なペプチドの場合, これは、製剤が無菌配合された無菌製剤でなければならないことを意味します (CSP) USPによって管理される <797>.

503A の配合に使用される原薬は、FDA 登録施設から供給され、分析証明書が添付されている必要があります。. 「研究使用のみ」または「実験室使用のみ」と書かれたラベルは、明らかに失格です。 一般章に関する USP の解説 <797> CSPの配合に使用される物質にそのような文言を表示してはならないと規定している.

503B アウトソーシング施設

503B アウトソーシング施設は、患者固有の処方箋なしでオフィス在庫または医療施設で使用できるように大規模に複合化されています。. 503B未満, FDAの監視が大幅に強化される: 施設はFDAに登録する必要があります, cGMPに準拠, FDAの検査の対象となります. 最終製品はまだFDAの承認を受けていない, しかし、期待される製造規律は従来の医薬品製造の規律に近づきます。.

研究用途のみ (それまで) カスタム合成

Research-use-only peptides occupy a legally distinct category. They are manufactured for laboratory research, not for human administration, and are not intended to enter the compounding pathway. Regulatory guidance is consistent that high HPLC purity and a CoA do not convert an RUO material into a permissible compounding API. The intended use and the supplier’s FDA registration status — not the analytical data alone — determine whether a material is appropriate for a compounding application.

Biopharma R のカスタム合成&D

Custom synthesis for biopharma R&D sits in an analytically demanding middle ground. The material is not intended for human administration (at the preclinical stage), but it may be used in animal studies, in vitro assays, or IND-enabling studies that have direct regulatory implications. The quality documentation requirements for these materials are determined by the intended use and the quality system of the receiving institution — not by a single universal standard. But the analytical bar is rising.

規制された医薬品の製造

Full cGMP drug manufacturing covers FDA-approved or regulated finished drug products. ここ, the impurity profiling, validated analytical methods, full batch records, and release specifications are non-negotiable and subject to regulatory review. This is the reference ceiling against which other quality tiers are increasingly compared.

What USP <797>’s 2023 実際に変更されたリビジョン

The November 2023 revision of USP General Chapter <797> replaced the prior low-/medium-/high-risk framework with a two-category system — Category 1 とカテゴリー 2 — based primarily on whether enhanced microbial testing is performed and what beyond-use dating (つぼみ) is assigned.

Category 1 CSPs allow a BUD of 12 hours at controlled room temperature or 24 hours at refrigerated temperature, without requiring enhanced environmental monitoring or sterility testing.

Category 2 CSPs allow longer BUDs (まで 45 days at refrigerated temperature under certain conditions) but require substantially more: sterility and endotoxin testing, enhanced environmental monitoring with surface sampling monthly in conjunction with media fill testing, and more frequent viable air sampling for Category 2 CSPs than for Category 1.

The practical quality implications extend beyond pharmacy operations:

• Environmental monitoring is now more granular and more frequent, particularly for preparations with extended BUDs. Air sampling frequency, surface contamination testing intervals, and temperature/humidity recording requirements are all specified.

• Personnel qualification now includes role-based training, garbing competency, gloved fingertip testing, and media-fill competency assessments at defined intervals.

• Documentation depth has increased: cleaning and disinfection records, environmental control logs, validation records, and release-testing documentation are all required and auditable.

• Beyond-use dating is tied to demonstrated controls, not just preparation category. A supplier claiming extended stability without the environmental monitoring and testing record to support it is making an unverifiable claim.

These requirements define what a demonstrably controlled sterile manufacturing environment looks like. They do not formally apply to RUO custom synthesis. But they do establish a documentation vocabulary that rigorous buyers now apply to vendor audits across the board.

トレーサビリティ: 複雑な精査によって明らかになった加工流通基準

Traceability in the compounding context means something specific: the ability to trace a preparation backward through its bulk API lot, the testing that was performed on that lot, the personnel involved in compounding, the environmental conditions at the time of compounding, and forward through storage and dispensing. This is what a regulatorily defensible batch record looks like.

For research-grade custom synthesis, the traceability standard has historically been lower: a lot number on the vial, a CoA with HPLC and MS data, and a shipping record. That is no longer sufficient for materials destined for in vivo studies, IND-enabling work, or institutional procurement with formal quality agreements.

What a defensible traceability package now includes:

• Unique batch/lot identifier that matches the CoA, the physical vial label, and the raw analytical data from which the CoA was generated

• Raw-material chain of custody: which amino acid, 樹脂, and reagent lots were used, with their own supplier-issued CoAs

• ペプチド合成 Synthesis and purification records: SPPS coupling conditions, deprotection sequences, 切断条件, 精製方法 (RP-HPLC with column and mobile phase documented), and step yield at each stage

• Release testing linkage: the CoA must be derived from lot-specific testing, not template-populated from a prior batch or a reference standard run on a different lot

• Storage and shipping conditions: 温度 合成ペプチド excursion records if cold-chain is required

MOL Changes maintains a complete product quality traceability system in which each batch carries a unique identification code that records personnel, process steps, and environmental conditions from upstream synthesis through lyophilization and shipment — the model for what peptide supplier governance for raw materials and sterilization should look like.

The most common traceability failure in the research peptide market is not fabrication — it is template reuse. A CoA that shows the same chromatogram peak shape across multiple lot numbers, or a batch document where the “lot ID” is the only field changed, is not a traceability record. It is a data integrity failure.

⚠️警告: A CoA generated from a reference standard or prior batch run — rather than the actual lot being shipped — is a traceability failure regardless of how accurate the purity number appears. Request the raw HPLC integration table and MS spectrum to verify lot-specific data generation.

不純物プロファイリング: 研究グレードとGMPグレードが最も大きく異なる次元

The impurity profile of a synthetic peptide is not simply what is left after the main peak. It is a structured record of every peptide-related species above a defined reporting threshold, with structural identification for species above the identification threshold, and a qualification assessment for species above the qualification threshold.

For pharmaceutical manufacturing, the regulatory framework is now explicit. The EMA synthetic peptide guideline (effective June 2026) セット:

• 報告しきい値: >0.1% relative to drug substance

• Identification threshold: >0.5%

• Qualification threshold: >1.0%

Each impurity above these thresholds requires structural characterization — typically by orthogonal analytical methods covering size, 充電, and hydrophobicity — not HPLC alone. あ 2026 GMP peptide manufacturing compliance analysis notes that HPLC alone is insufficient for a complete impurity profile and that UHPLC-HRMS/MS is expected for peak identity confirmation at this level.

For a first GMP lot, typical acceptance criteria require HPLC purity >97% with no single impurity exceeding 1% — per established peptide quality control references, のような Polypeptide’s quality control specifications. This is not the same as a general-research standard of ≥95% HPLC purity, where impurities are summarized as “everything other than the main peak” without individual characterization.

The practical implications for research procurement:

The gap between these two documentation tiers is what makes “research-grade” a meaningful specification rather than a marketing label. Buyers who receive a CoA showing 95.2% HPLC purity with no further detail are receiving a material that may be entirely appropriate for in vitro binding assays or computational validation work — and entirely inappropriate for rodent pharmacokinetics, stability studies, or IND-enabling toxicology. The CoA does not make that distinction explicit; the buyer must.

The batch-specific CoA component architecture — traceability header, raw RP-HPLC data, HR-MS spectra, and counterion reporting — that research institutions are increasingly adopting mirrors what GMP-adjacent programs demand. The practical distinction is between documentation that describes a material and documentation that a receiving quality system can independently verify.

分析証明書: 防御可能な文書には実際に何が含まれているか

A Certificate of Analysis is not a supplier’s affidavit that material is good. It is a primary analytical record linking a specific lot of material to specific test results generated by a defined method at a specific laboratory. When the CoA is constructed correctly, every claim it contains is reproducible and auditable.

The minimum elements for a defensible research-grade CoA are:

1. Peptide identification: full sequence, molecular formula, 分子量 (confirmed by MS, not calculated from sequence alone), and CAS number where applicable

2. Batch/lot traceability: unique alphanumeric lot identifier matching the vial label

3. Synthesis date and stated shelf life under the specified storage conditions

4. HPLC純度: expressed as percentage by peak area, with the analytical method specified — column, 移動相, wavelength (通常 214 nm for peptide backbone), and gradient conditions

5. MSの身元確認: measured molecular weight from ESI-MS or MALDI-TOF, not simply the calculated value

6. Testing laboratory identity and credentials: who performed the analysis and when

For materials intended for in vivo injectable use, 追加: 7. Endotoxin testing: method (typically LAL per USP <85>), result, and acceptance criterion 8. Sterility testing: method (per USP <71>) and result 9. Residual TFA quantification: with counterion exchange data if acetate or HCl salt form is required 10. 残留溶剤: reported per ICH Q3C

A broader audit framework for evaluating third-party documentation quality — including how to assess whether a CoA represents lot-specific versus template-populated data — is available in the beyond-the-CoA peptide testing audit guide.

重要なポイント: HPLC purity percentage is a single-point summary. The CoA elements that verify it — the raw chromatogram with integration table, the column and method documentation, the lot ID match — are what distinguish an analytical record from a formatted assertion.

The structural characteristics of a fraudulent or template-reused CoA are recognizable: identical peak shapes across lot numbers, purity values that cluster suspiciously (例えば, always 98.3%), absence of a method note, and a testing laboratory that is either unnamed or cannot be independently verified. These are not hypothetical edge cases — they represent documented patterns in the research peptide market.

公開 CoA が明らかにするもの: ドキュメントの完全性のスナップショット

The following observations are drawn from MOL Changes’ review of publicly posted and client-submitted peptide Certificates of Analysis across research-grade suppliers, anonymized and aggregated. They are intended to illustrate recurring documentation gaps, not to characterize any individual supplier.

Across the CoAs reviewed, three gaps recurred most often:

• Missing raw chromatogram data. A majority of research-grade CoAs stated a purity percentage without attaching the underlying RP-HPLC chromatogram and integration table. Without the raw trace, the stated percentage cannot be independently verified.

• Template-populated identity fields. A recurring pattern was a CoA in which molecular weight appeared as a calculated value rather than a measured one, with no accompanying MS spectrum. This does not prove a defect, but it removes the primary evidence that the shipped lot matches the stated sequence.

• Absent method documentation. Column type, 移動相, 勾配, and detection wavelength were frequently unspecified, making the purity figure non-reproducible by a receiving laboratory.

How to use this snapshot. These observations describe the distribution of documentation completeness, not the frequency of fraud. Most gaps reflect process maturity rather than intent. The practical takeaway is that completeness varies considerably across the research-grade market, and a buyer who does not specify required CoA elements in advance will receive whatever the supplier’s default template contains.

注記: The observations above are aggregated and anonymized. Specific figures and named examples will be added from MOL Changes’ internal audit records on request; readers should treat this section as indicative of documentation patterns rather than a statistically representative market survey.

目的に合った主張: ペプチド調達において最も乱用され、最も定義されていないラベル

“Fit for purpose” is not a quality specification. It is a procurement conclusion. The phrase is used, correctly, to mean that a material’s documented quality attributes are appropriate for the intended application — and is used, incorrectly, as a marketing shortcut for “good enough” without specifying what “good enough” means for what application.

The regulatory scrutiny on compounding has sharpened what fit-for-purpose means in practice by forcing an explicit mapping of quality attributes to intended use. The same mapping discipline belongs in research procurement.

A practical framework:

Thresholds reflect commonly applied industry practice and published regulatory guidance; acceptance criteria should be confirmed with the appropriate regulatory authority for the specific study design.

The fit-for-purpose decision is a responsibility that belongs to the buyer, サプライヤーではありません. A custom synthesis provider can document what a material is. Only the receiving team can determine whether those attributes are sufficient for the study type in which the material will be used. Accepting a “research grade” label without mapping it to specific analytical attributes — and then expecting the material to perform in a rodent GLP study — is a procurement failure, not a supplier failure.

This framing applies directly to the compounding scrutiny context. When a compounding pharmacy sources a bulk peptide API and that API lacks a documented impurity profile, the compounder cannot perform a meaningful release assessment. When a research team sources a custom peptide and the CoA lacks endotoxin data, the team cannot make an informed decision about whether the material is appropriate for an animal study. The documentation gap is structurally the same even though the regulatory category is different.

The emerging field standard is that buyers request a tier-specific documentation confirmation before purchase order release, not after — a practice that requires the supplier to publish, or at least commit to, the documentation package associated with each use tier in advance.

The Supplier’s Obligation: 精査を証明する文書とはどのようなものなのか

The compounding quality conversation has clarified what documentation capable of surviving regulatory review actually requires. For custom synthesis providers serving biopharma R&D, the practical translation is a commitment to lot-specific analytical transparency rather than template-generated summary data.

The elements that define a documentation-ready custom synthesis supplier:

Analytical infrastructure

• RP-HPLC purity data with raw chromatogram output (not just a summary percentage)

• 高分解能質量分析: ESI-HRMS or MALDI-TOF with mass accuracy <5 ppm where required

• Orthogonal characterization for materials above basic research grade: 元, SEC-HPLC, or CE as appropriate to the peptide class

• Endotoxin testing capability per USP <85> (LAL法)

• Sterility testing capability per USP <71>

• Residual solvent analysis and counterion quantification

Manufacturing environment

• Demonstrated sterile manufacturing capability for injectable-grade materials — typically a classified ISO environment with documented environmental monitoring, not merely a stated commitment to clean conditions

• Separation of research-grade and sterile-grade processing streams to prevent cross-contamination

Quality management

• Lot-specific CoA generation linked to raw analytical data, not template population

• Batch record documentation connecting synthesis, 精製, and testing steps to the released lot

• Formal deviation and non-conformance handling with documented outcomes

MOL Changes operates within a クラス 100 cleanroom manufacturing environment with a complete product quality traceability system — recording personnel involvement, プロセスパラメータ, excipient and reagent lots, and environmental conditions from synthesis through lyophilization and shipment. For biopharma buyers evaluating whether a custom synthesis partner can support the quality documentation that their internal quality system or regulatory program requires, the baseline question is whether this infrastructure is demonstrated or merely described.

これが調達実務にとって何を意味するか

The practical response to compounding scrutiny, for biopharma R&D 意思決定者, is a quality intake process that explicitly ties procurement criteria to application type before purchase order release.

Three immediate actions that align procurement with the current quality landscape:

1. Require a use-tier classification at PO submission. Before placing an order, define in writing whether the material is intended for in vitro assays, cell-based assays, rodent in vivo studies, IND-enabling work, or clinical use. This classification determines the minimum CoA requirements and sterility specifications that apply.

2. Request the raw analytical data, not just the CoA summary. Ask the supplier for the unredacted RP-HPLC chromatogram with the integration table, the HR-MS spectrum showing the charge state distribution and mass accuracy, and the endotoxin testing report if applicable. If a supplier cannot provide these, the CoA is not independently verifiable.

3. Audit the traceability path. Confirm that the lot ID on the vial matches the lot ID on the CoA, which matches the lot ID in the raw analytical data, which matches the batch record that documents the synthesis and purification conditions. A missing link in this chain is a documentation failure, regardless of what the purity number says.

Documented patterns in the consumer peptide market point to the same structural cause: buyers accepting CoA summaries at face value rather than verifying the analytical record from which the summary was generated. The failure mode is not a bad analytical result — it is the absence of the underlying record that would let a third party confirm one was ever produced. ペプチドの生産

The compounding standard — specifically the requirement that CSP release documentation be auditable, lot-specific, and traceable to the analytical method used — is the right model for this verification practice, regardless of whether the material being procured is technically a compounded drug.

リスクを理解しているカスタム合成パートナーと協力する

If your program is operating at the boundary where research-grade quality governance is no longer adequate — scaling toward IND-enabling studies, moving from in vitro to in vivo work, or working with peptide sequences that require complex modifications and clean impurity profiles — the synthesis partner conversation needs to start with documentation architecture, not just purity percentage.

MOL Changes provides custom and catalog peptide synthesis supported by Class 100 無菌クリーンルームでの製造, full HPLC and MS analytical verification, endotoxin and sterility testing capability, and a lot-specific traceability system covering synthesis through shipment. バイオファーマR向け&D teams that need a technical feasibility assessment for a specific sequence — including discussion of the expected impurity profile, sterility requirements, and documentation package for the intended study type — that conversation is the appropriate starting point.

開示: MOL Changes is a commercial peptide synthesis provider with a direct commercial interest in the quality standards discussed in this article. This article is prepared for educational purposes and separates regulatory requirements from industry best practices and supplier-specific standards where possible. All regulatory thresholds and quality specifications cited are drawn from publicly available guidance documents and peer-reviewed sources, as listed in the References section. Content is written by the MOL Changes Technical Team and reviewed by its Quality & Regulatory Affairs Group; it is not independently peer-reviewed by a third party.

For technical questions about documentation requirements for specific peptide sequences or study types, contact the MOL Changes synthesis team at molchanges.com.

参考文献

US Pharmacopeia

• USP総章 <797> Pharmaceutical Compounding — Sterile Preparations (revised November 2023). 米国薬局方.

• USP総章 <795> Pharmaceutical Compounding — Nonsterile Preparations. 米国薬局方.

• USP総章 <71> 無菌試験. 米国薬局方.

• USP総章 <85> 細菌エンドトキシン検査. 米国薬局方.

• 米国薬局. Commentary on General Chapter <797> (2022). https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/usp-nf-commentary/797-commentary-20221101.pdf

US Food and Drug Administration

• FDA. Pharmacy Compounding Advisory Committee Meeting Materials (7月 2026). https://www.fda.gov/media/193773/download

• FDA. Compounding and FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

• FDA. Compounding Law and Related Guidance (Section 503A and 503B of the FD&C法).

欧州医薬品庁

• EMA. 合成ペプチドの開発・製造に関するガイドライン (effective June 2026).

私

• IQ3C(R8). 不純物: 残留溶剤に関するガイドライン. 国際調和評議会.

Additional industry references cited in text

• Neolab Peptides. GMP Peptide Manufacturing 2026 コンプライアンスガイド. https://neolabpeptides.com/blogs/news/gmp-peptide-manufacturing-2026-compliance-guide

• Polypeptide Group. Quality Control Specifications. https://www.polypeptide.com/services/quality-control/

• 商船三井の変更点. ペプチドサプライヤーのガバナンス: Raw Materials and Sterilization. https://molchanges.com/peptide-supplier-governance-raw-materials-sterilization.html

• 商船三井の変更点. Beyond the CoA: 第三者ペプチド検査監査ガイド. https://molchanges.com/beyond-the-coa-third-party-peptide-testing-audit-guide.html

For technical questions about documentation requirements for specific peptide sequences or study types, contact the MOL Changes synthesis team at molchanges.com.